Research programme: VCAM-1 inhibitors - Pfizer

Drug Profile

Research programme: VCAM-1 inhibitors - Pfizer

Alternative Names: CP 609643; CP 619700; CP 664511

Latest Information Update: 05 Sep 2006

Price : $50

At a glance

  • Originator Pfizer
  • Class Small molecules
  • Mechanism of Action Immunosuppressants; Vascular cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic asthma; Respiratory tract disorders

Most Recent Events

  • 05 Sep 2006 Discontinued - Preclinical for Respiratory tract disorders in USA (unspecified route)
  • 05 Sep 2006 Discontinued - Preclinical for Allergic asthma in USA (unspecified route)
  • 31 Jan 2001 Preclinical trials in Respiratory tract disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top